Former CEO Avizorex Pharma (acquired by Aerie Pharmaceuticals) developing AR-15512 (formerly AVX-012), currently in Phase 3 for Dry Eye Disease. Co-founder of Disrupt Therapeutics, a UPF Spin-off developing a novel drug candidate for Cognitive Impairment due to Medical Cannabis use in pain Management.